Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

Cited In for PubMed (Select 12704383)

1.
2.

Inhibition of protein kinase C by isojacareubin suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo.

Yuan X, Chen H, Li X, Dai M, Zeng H, Shan L, Sun Q, Zhang W.

Sci Rep. 2015 Aug 6;5:12889. doi: 10.1038/srep12889.

3.

Assays for predicting and monitoring responses to lung cancer immunotherapy.

Teixidó C, Karachaliou N, González-Cao M, Morales-Espinosa D, Rosell R.

Cancer Biol Med. 2015 Jun;12(2):87-95. doi: 10.7497/j.issn.2095-3941.2015.0019. Review.

4.

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

Wu AA, Drake V, Huang HS, Chiu S, Zheng L.

Oncoimmunology. 2015 Apr 1;4(7):e1016700. eCollection 2015 Jul. Review.

PMID:
26140242
5.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

PMID:
26137416
6.

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008814. eCollection 2015 Apr. Review.

PMID:
26137403
7.

PD-L1 and Survival in Solid Tumors: A Meta-Analysis.

Wu P, Wu D, Li L, Chai Y, Huang J.

PLoS One. 2015 Jun 26;10(6):e0131403. doi: 10.1371/journal.pone.0131403. eCollection 2015.

8.

Radiotherapy suppressed tumor-specific recruitment of regulator T cells via up-regulating microR-545 in Lewis lung carcinoma cells.

Liao C, Xiao W, Zhu N, Liu Z, Yang J, Wang Y, Hong M.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2535-44. eCollection 2015.

9.

Targeting hypoxia at the forefront of anticancer immune responses.

Noman MZ, Chouaib S.

Oncoimmunology. 2015 Jan 7;3(12):e954463. eCollection 2014 Dec.

PMID:
25964858
10.

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.

Leone RD, Lo YC, Powell JD.

Comput Struct Biotechnol J. 2015 Apr 8;13:265-72. doi: 10.1016/j.csbj.2015.03.008. eCollection 2015. Review.

11.

Immune checkpoint blockade: a common denominator approach to cancer therapy.

Topalian SL, Drake CG, Pardoll DM.

Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6. Review.

PMID:
25858804
12.

Hypoxia-inducible factors in cancer stem cells and inflammation.

Peng G, Liu Y.

Trends Pharmacol Sci. 2015 Jun;36(6):374-83. doi: 10.1016/j.tips.2015.03.003. Epub 2015 Apr 6. Review.

PMID:
25857287
13.

ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy.

Li C, Li W, Xiao J, Jiao S, Teng F, Xue S, Zhang C, Sheng C, Leng Q, Rudd CE, Wei B, Wang H.

EMBO Mol Med. 2015 Apr 7;7(6):754-69. doi: 10.15252/emmm.201404578.

14.

PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.

McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, Seiffert M.

Blood. 2015 Jul 9;126(2):203-11. doi: 10.1182/blood-2015-01-622936. Epub 2015 Mar 23.

PMID:
25800048
15.

Overcoming T cell exhaustion in infection and cancer.

Pauken KE, Wherry EJ.

Trends Immunol. 2015 Apr;36(4):265-76. doi: 10.1016/j.it.2015.02.008. Epub 2015 Mar 18. Review.

PMID:
25797516
16.

Tumor-infiltrating dendritic cells in cancer pathogenesis.

Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL.

J Immunol. 2015 Apr 1;194(7):2985-91. doi: 10.4049/jimmunol.1403134. Review.

PMID:
25795789
17.

B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor.

Yang Y, Wu KE, Zhao E, Li W, Shi L, Xie G, Jiang B, Wang Y, Li R, Zhang P, Shuai X, Wang G, Tao K.

Oncol Lett. 2015 Apr;9(4):1833-1838. Epub 2015 Feb 10.

18.

Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway.

Yu Q, Lou XM, He Y.

PLoS One. 2015 Mar 13;10(3):e0120855. doi: 10.1371/journal.pone.0120855. eCollection 2015.

19.

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

Linch SN, McNamara MJ, Redmond WL.

Front Oncol. 2015 Feb 16;5:34. doi: 10.3389/fonc.2015.00034. eCollection 2015. Review.

PMID:
25763356
Free PMC Article
20.

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH.

Cancer Immunol Res. 2015 Apr;3(4):399-411. doi: 10.1158/2326-6066.CIR-14-0215. Epub 2015 Feb 12.

PMID:
25678581
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk